380 related articles for article (PubMed ID: 3086360)
1. Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel.
Elkik F; Basdevant A; Jackanicz TM; Guy-Grand B; Mercier-Bodard C; Conard J; Bardin CW; Corvol P
J Clin Endocrinol Metab; 1986 Jul; 63(1):29-35. PubMed ID: 3086360
[TBL] [Abstract][Full Text] [Related]
2. [Contraception in the hypertensive woman using a vaginal ring delivering estradiol and norgestrel].
Elkik F; Basdevant A; Corvol P
Arch Mal Coeur Vaiss; 1985 Oct; 78(11):1737-9. PubMed ID: 3938250
[TBL] [Abstract][Full Text] [Related]
3. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
4. [Vaginal ring contraception in hypertensive women].
Basdevant A; Elkik F; Guy-grand B; Conard J; Corvol P
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):365-7. PubMed ID: 12280208
[TBL] [Abstract][Full Text] [Related]
5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
7. Current status of research and development of vaginal contraceptive rings as a fertility control method in the female.
Roy S; Mishell Dr
Res Front Fertil Regul; 1983 May; 2(4):1-10. PubMed ID: 12227323
[TBL] [Abstract][Full Text] [Related]
8. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
[TBL] [Abstract][Full Text] [Related]
9. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
10. Metabolic changes during treatment with two different progestogens.
Refn H; Kjaer A; Lebech AM; Borggaard B; Schierup L; Bremmelgaard A
Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):374-7. PubMed ID: 2115298
[TBL] [Abstract][Full Text] [Related]
11. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
Cekan SZ; Jia M; Landgren BM; Diczfalusy E
Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.
Alvarez-Sanchez F; Brache V; Jackanicz T; Faundes A
Contraception; 1992 Oct; 46(4):387-98. PubMed ID: 1486777
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of a contraceptive vaginal ring releasing norethindrone and estradiol: ovarian function, bleeding control and lipoprotein patterns.
Victor A; Lithell H; Selinus I; Vessby B
Ups J Med Sci; 1984; 89(2):179-88. PubMed ID: 6380076
[TBL] [Abstract][Full Text] [Related]
14. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.
Mishell DR; Moore DE; Roy S; Brenner PF; Page MA
Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
16. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. I-Use effectiveness. An international comparative trial.
Sivin I; Mishell DR; Victor A; Diaz S; Alvarez-Sanchez F; Nielsen NC; Akinla O; Pyorala T; Coutinho E; Faundes A; Roy S; Brenner PF; Ahren T; Pavez M; Brache V; Giwa-Osagie OF; Fasan MO; Zausner-Guelman B; Darze E; Gama daSilva JC; Diaz J; Jackanicz TM; Stern J; Nash HA
Contraception; 1981 Oct; 24(4):341-58. PubMed ID: 6459208
[TBL] [Abstract][Full Text] [Related]
17. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
[TBL] [Abstract][Full Text] [Related]
18. Intravaginal contraception with the synthetic progestin, R2010.
Toivonen J
Contraception; 1979 Nov; 20(5):511-8. PubMed ID: 527342
[TBL] [Abstract][Full Text] [Related]
19. Some observations on the changes in capillary resistance in oral contraceptive users.
Zaki K; Younis MN; Razek SA; Mekkawi TE; Nour H
Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):145-51. PubMed ID: 12256025
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
Goebelsmann U; Mashchak CA; Mishell DR
Am J Obstet Gynecol; 1985 Apr; 151(7):868-77. PubMed ID: 3920910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
